Antiprotozoal Agents

Correct Answer

B — Nitroimidazole

Rationale

Metronidazole belongs to the nitroimidazole class, which also includes tinidazole and secnidazole. All nitroimidazoles share a 5-nitroimidazole scaffold and are active against anaerobic and microaerophilic organisms. Pentavalent antimonials (meglumine antimoniate, sodium stibogluconate) are used for leishmaniasis. Trypanocidal agents such as melarsoprol, eflornithine, and nifurtimox target African or American trypanosomiasis. Folate antagonists such as pyrimethamine act by inhibiting dihydrofolate reductase.

Correct Answer

C — Stage 2 African trypanosomiasis

Rationale

Eflornithine is indicated for stage 2 African trypanosomiasis — the meningoencephalitic stage, in which Trypanosoma brucei gambiense has crossed the blood-brain barrier. It is used as part of the nifurtimox-eflornithine combination therapy regimen, which replaced melarsoprol as standard of care for stage 2 gambiense sleeping sickness. Stage 1 disease (hemolymphatic) does not require a drug with central nervous system penetration. Eflornithine is not used for leishmaniasis, and toxoplasmosis is treated with pyrimethamine-sulfadiazine or alternative regimens.

Correct Answer

A — Chagas disease

Rationale

Benznidazole is one of only two drugs approved for Chagas disease (American trypanosomiasis, caused by Trypanosoma cruzi); the other is nifurtimox. Both are nitroheterocyclic compounds most effective in the acute phase of infection. African trypanosomiasis is treated with suramin, pentamidine, melarsoprol, or nifurtimox-eflornithine combination therapy depending on species and stage. Visceral leishmaniasis is treated with liposomal amphotericin B, miltefosine, or pentavalent antimonials. Toxoplasmosis is treated with pyrimethamine-sulfadiazine.

Correct Answer

D — Visceral leishmaniasis

Rationale

Liposomal amphotericin B is a first-line treatment for visceral leishmaniasis (kala-azar), the most severe form of Leishmania infection. The liposomal formulation is preferentially taken up by macrophages — the very cells in which Leishmania amastigotes reside — delivering the drug directly to the intracellular site of infection while reducing the nephrotoxicity associated with conventional amphotericin B. It is not used for toxoplasmosis (pyrimethamine-sulfadiazine), Chagas disease (benznidazole, nifurtimox), or African trypanosomiasis (stage-specific agents).

Correct Answer

B — Folate antagonist

Rationale

Pyrimethamine is classified as a folate antagonist — specifically a dihydrofolate reductase inhibitor. It blocks folate reduction in protozoan parasites, depriving them of the reduced folate cofactors required for nucleotide synthesis and cell division. It is paired with sulfadiazine (a folate synthesis inhibitor) for the treatment of toxoplasmosis. Nitroimidazoles (metronidazole, tinidazole) act by generating toxic radical intermediates that damage parasite genetic material. Pentavalent antimonials target Leishmania amastigotes. Trypanocidal agents target African or American trypanosomes.

Correct Answer

C — It is an oral antileishmanial agent — the first effective oral treatment for visceral leishmaniasis

Rationale

Miltefosine is the first and currently the only oral drug approved for visceral leishmaniasis, representing a significant advantage over agents requiring parenteral administration. Its oral bioavailability makes it suitable for outpatient use in endemic regions where intravenous or intramuscular administration is logistically difficult. Pentavalent antimonials (meglumine antimoniate, sodium stibogluconate) are given parenterally and are not oral agents. Miltefosine is not a folate antagonist and does not require leucovorin supplementation. It is not a nitroimidazole and is not related to the metronidazole class.

Correct Answer

A — The nitro group is reduced by anaerobic electron transport systems inside the organism, generating toxic radical intermediates that disrupt genetic material and kill the cell

Rationale

Metronidazole is a prodrug. Its nitro group is reduced by low-redox-potential electron transport components present only in anaerobic and microaerophilic organisms. This reduction generates short-lived toxic radical species that damage the organism's genetic material, causing strand breaks and cell death. Because aerobic organisms lack the reducing environment needed for this activation step, they are not harmed — which explains metronidazole's selective toxicity. Dihydrofolate reductase inhibition describes pyrimethamine. Membrane phospholipid disruption is not the mechanism. Ornithine decarboxylase inhibition describes eflornithine.

Correct Answer

C — Eflornithine irreversibly inhibits ornithine decarboxylase, depleting the polyamines the parasite requires for growth and replication

Rationale

Eflornithine is an irreversible inhibitor of ornithine decarboxylase, the enzyme that catalyzes the first committed step in polyamine biosynthesis. Trypanosoma brucei gambiense depends on polyamines for the synthesis of trypanothione — a unique thiol antioxidant found in trypanosomatids — and for cell growth and division. Eflornithine's selectivity for the trypanosomal enzyme over the human enzyme reflects a much shorter half-life of the human enzyme, allowing human cells to recover while the parasite cannot. Free radical generation describes benznidazole and nifurtimox. Dihydrofolate reductase inhibition describes pyrimethamine. Ergosterol binding describes amphotericin B.

Correct Answer

B — Benznidazole undergoes nitroreduction inside the parasite, generating reactive intermediates that damage trypanosomal genetic material, proteins, and lipids

Rationale

Benznidazole is a nitroimidazole prodrug activated by nitroreductases within Trypanosoma cruzi. Reduction of the nitro group generates reactive radical intermediates that cause widespread macromolecular damage — attacking genetic material, proteins, and membrane lipids. This multi-target damage is consistent with the broad macromolecular injury seen with other activated nitroheterocyclic compounds. The mechanism shares the nitroreductive activation principle with nifurtimox, the other drug used for Chagas disease. Ornithine decarboxylase inhibition describes eflornithine (used in African trypanosomiasis, not Chagas disease). Folate blockade describes pyrimethamine-sulfadiazine. Ergosterol binding describes amphotericin B.

Correct Answer

D — The liposomal formulation is preferentially taken up by macrophages, delivering amphotericin B directly to the intracellular compartment where Leishmania amastigotes reside

Rationale

Leishmania amastigotes live inside macrophages, making intracellular drug delivery essential for effective treatment. Liposomes are natural targets for macrophage phagocytosis; the liposomal amphotericin B formulation exploits this to concentrate drug precisely in the cells where the parasite hides. This targeted delivery improves efficacy while simultaneously reducing systemic exposure — particularly nephrotoxicity, which limits conventional amphotericin B. The mechanism of action against the parasite (ergosterol binding causing membrane permeabilization) is unchanged between formulations; what differs is drug delivery, not the pharmacodynamic target. Dosing schedule differences and bypass of intracellular activation are not the pharmacological basis for preference.

Correct Answer

A — The two drugs block sequential steps in the parasite folate pathway — sulfadiazine inhibits folate synthesis and pyrimethamine inhibits folate reduction — producing synergistic antiparasitic activity

Rationale

Pyrimethamine and sulfadiazine exemplify sequential pathway blockade: sulfadiazine (a sulfonamide) inhibits dihydropteroate synthase, blocking the synthesis of folate from its precursors, while pyrimethamine inhibits dihydrofolate reductase, blocking the conversion of folate to its active reduced form. Together they deprive Toxoplasma gondii of the reduced folate cofactors required for nucleotide synthesis and cell division — an effect that is synergistic because blocking both steps is far more lethal than blocking either alone. Leucovorin (folinic acid) is added to this regimen to rescue human cells, which can use preformed folate from the diet that the parasite cannot access. The combination is not based on efflux inhibition, oxidative stress, or prodrug activation.

Correct Answer

C — Metronidazole requires a low-redox-potential intracellular environment for reductive activation; aerobic cells maintain a high-redox environment that prevents this activation

Rationale

Metronidazole is a prodrug that must be reduced to generate its toxic radical intermediates. This reduction occurs only in organisms with low-redox-potential electron carriers — conditions found in anaerobic and microaerophilic organisms. In aerobic cells, the intracellular environment is oxidizing rather than reducing; metronidazole enters the cell freely but cannot be reduced to its active form, so no toxic intermediates are produced and the drug is harmless. This redox-dependent activation is the mechanistic basis for metronidazole's selective toxicity. Efflux transporter expression, sulfoxide inactivation, and absence of a surface receptor do not account for this selectivity.

Correct Answer

B — Nifurtimox is reduced inside the parasite to reactive intermediates that generate oxidative stress, overwhelming the trypanosome's trypanothione-based antioxidant system

Rationale

Nifurtimox is a nitrofuran compound that undergoes reductive activation inside trypanosomes, generating reactive oxygen species. Trypanosomatids depend on trypanothione — a unique thiol compound found only in these parasites — as their primary antioxidant defense. Nifurtimox-generated oxidative stress overwhelms this trypanothione system, causing parasite death. Because human cells use a different antioxidant system (glutathione-based), there is a degree of selectivity, though nifurtimox does have significant adverse effects. In the nifurtimox-eflornithine combination therapy regimen, nifurtimox contributes oxidative parasite killing while eflornithine depletes polyamine synthesis. Ornithine decarboxylase inhibition describes eflornithine specifically. Folate reduction blockade describes pyrimethamine. Ergosterol binding describes amphotericin B.

Correct Answer

D — They are converted to the active trivalent form within macrophages and inhibit enzymes critical for Leishmania energy metabolism and trypanothione synthesis

Rationale

Pentavalent antimonials are prodrugs that require activation to their trivalent antimony form, a conversion that occurs within the macrophage — the cell in which Leishmania amastigotes reside. The trivalent form inhibits enzymes involved in parasite energy metabolism and in the trypanothione antioxidant system that trypanosomatids depend on for protection against oxidative stress. This intramacrophage activation concentrates drug activity at the site of infection. The mechanism differs from ergosterol binding (amphotericin B), macrophage-generated free radicals (not an established mechanism for antimonials), and ornithine decarboxylase inhibition (eflornithine).

Correct Answer

A — Pyrimethamine plus sulfadiazine

Rationale

The clinical presentation — ring-enhancing brain lesions in a severely immunocompromised patient with positive Toxoplasma serology — is classic for cerebral toxoplasmosis. The question asks for the pharmacotherapy that works by blocking two sequential steps in the parasite folate pathway. Pyrimethamine inhibits dihydrofolate reductase and sulfadiazine inhibits dihydropteroate synthase, together producing sequential blockade that deprives the parasite of reduced folate needed for nucleotide synthesis. Leucovorin is added in practice to protect the host. Metronidazole plus tinidazole combines two nitroimidazoles with no anti-Toxoplasma activity. Eflornithine plus nifurtimox is the regimen for stage 2 African trypanosomiasis. Liposomal amphotericin B plus miltefosine targets visceral leishmaniasis.

Correct Answer

C — Metronidazole inhibits aldehyde dehydrogenase, causing acetaldehyde to accumulate after ethanol ingestion and producing a disulfiram-like reaction

Rationale

Ethanol is metabolized in two steps: alcohol dehydrogenase converts it to acetaldehyde, then aldehyde dehydrogenase converts acetaldehyde to acetate. Metronidazole inhibits aldehyde dehydrogenase, so when alcohol is consumed during treatment, acetaldehyde accumulates rather than being cleared. Acetaldehyde causes vasodilation, flushing, nausea, vomiting, and tachycardia — the disulfiram-like reaction seen here. Patients must be counseled to avoid all alcohol during metronidazole treatment and for at least 48 hours after the last dose. This is not a cytochrome P450-mediated interaction, not a plasma protein binding effect, and not related to renal tubular secretion of ethanol.

Correct Answer

B — HIV-associated immunosuppression prevents complete parasite clearance, leaving a residual parasite burden that causes relapse without secondary prophylaxis

Rationale

In immunocompetent patients, a functioning T-cell response helps sustain the antiparasitic effect of antileishmanial drugs after treatment is completed. In patients with advanced HIV infection, this immune response is absent; even after a clinically successful course of liposomal amphotericin B, residual Leishmania organisms persist in macrophages and cause relapse at a high rate — often within months. Secondary prophylaxis with liposomal amphotericin B given at regular intervals is therefore required in HIV-Leishmania coinfection to suppress this residual burden, and prophylaxis can be considered for discontinuation only when immune reconstitution on antiretroviral therapy raises the CD4 count to a sustained level above the threshold associated with relapse risk. HIV does not alter amphotericin B pharmacokinetics, does not convert parasites to a drug-resistant form, and does not cause drug trapping in the spleen.

Correct Answer

D — Toxoplasma gondii tissue cysts persist after acute treatment; in the absence of adequate immune function, cyst reactivation causes relapse, so secondary prophylaxis is required until immune reconstitution raises the CD4 count above the threshold for safe discontinuation

Rationale

Pyrimethamine-sulfadiazine clears the active tachyzoite stage of Toxoplasma gondii but does not eradicate tissue cysts. In immunocompetent individuals, the immune system keeps cysts dormant. In patients with advanced HIV and severely depressed CD4 counts, this immune surveillance is absent; cysts reactivate to produce new tachyzoites, and encephalitis recurs at high rates if secondary prophylaxis is stopped. The standard secondary prophylaxis regimen is continued at lower doses until antiretroviral therapy restores immune function — typically until the CD4 count has risen above 200 cells per microliter on two measurements taken at least three months apart. Pyrimethamine does not require tapering. Toxoplasma gondii does not form liver hypnozoites — that is a Plasmodium vivax concept. The rationale is not drug-specific central nervous system penetration.